HEALTH TECHNOLOGY

Innovaccer Expands Global Footprint, Enters U.K. Market to Deliver Digital Transformation in Healthcare

Innovaccer Inc., | June 24, 2022

Innovaccer Expands

The Health Cloud firm, Innovaccer Inc., declared that as part of its growth into the UK healthcare industry, it will build an office in London. To support the legislative reforms of the NHS Health and Care Act 2022, Innovaccer offers data-driven technological solutions that can speed up innovation and digital transformation. The company's long-term expansion strategy and dedication to improving healthcare access, affordability, and quality around the world are both supported by the opening of the London office.

The NHS recommended in 2019 that its design be changed in order to "improve coordination of services through the construction of Integrated Care Systems." The Health and Care Act of 2021 offered a framework to make it easier for the NHS, local governments, and other stakeholders to work together and promote the pandemic's recovery. The bill was enlarged by the Health and Care Act 2022, which included a wide variety of policy changes targeted at strengthening health and care services through improved integration of health and care and addressing growing health inequities.

“The UK healthcare landscape is one of the best in the world. NHS England’s long-term plan clearly sets the direction for widespread digital services that can support and empower people to stay healthy and independent for longer. But they also acknowledge the challenge of identifying a technology provider that’s experienced with healthcare data. With Innovaccer’s data and analytics platform backed by a unified patient record, we can move towards addressing inequalities in health and population health, as well as wellbeing and the quality of services as part of the triple aim for NHS”.

John Gurnett, General Manager, UK and Europe, Innovaccer

More than 1,600 care settings have used Innovaccer's solutions. Over 39 million patients' records have been merged, helping over 96,000 caregivers work more cooperatively and saving more than £800 million as a result. Leading healthcare organizations have seen results like a 6.6 percent decrease in emergency room use, a 6.6 percent decrease in readmissions, and a 13 percent increase in referral success rate.

This is a milestone for the company in achieving our vision and for healthcare. By integrating data from multiple domains within the NHS and from local agencies, Innovaccer can help bridge the collaboration gap and provide analytics and actionable insights to meet the goals as set out by the Health and Care Act 2022—to improve the quality of care and reduce costs. Innovaccer’s capabilities in care coordination and population health will accelerate NHS’s vision of enabling people to live healthier and more independent lives through high-quality, seamless care”.

Abhinav Shashank, co-founder and CEO of Innovac
 

Spotlight

Every day, in hospitals and physician offices everywhere, healthcare providers are telling patients what’s good for them: exercise, eat better, quit smoking. No one would deny this is great advice—but getting the patient to follow it can be a challenge for reasons most of us know too well. Ironically, some of these same providers find themselves playing the role of the resistant patient in the evolution of digital healthcare.

Spotlight

Every day, in hospitals and physician offices everywhere, healthcare providers are telling patients what’s good for them: exercise, eat better, quit smoking. No one would deny this is great advice—but getting the patient to follow it can be a challenge for reasons most of us know too well. Ironically, some of these same providers find themselves playing the role of the resistant patient in the evolution of digital healthcare.

Related News

HEALTH TECHNOLOGY

MedSec Sets Up a Healthcare Technology Cyber Risk Management Team

MedSec | July 04, 2022

In order to increase its biological and clinical knowledge, MedSec, a premier solutions provider of medical device security, announced it is forming a new Healthcare Technology Cyber Risk Management (HTCRM) team with a roster of seasoned professionals in the sector. The present Chief Product Officer of MedSec and HTCRM authority Phil Englert will take on the position of Advisor for the new team. "MedSec serves stakeholders of all kinds within the medical device eco-system. The establishment of this team allows us to better serve our hospital clients, who are tackling medical device security on a day-to-day basis." Justine Bone, CEO at MedSec "Biomedical and Clinical Engineering teams already have too many things on their plate – and they need leverage. Becoming an extension of their team, augmented by our technology capabilities, we're able to help our customers do things that they would otherwise not be capable of doing with their existing staff. Our clients love the combination of being able to 'speak tech' but also 'understand clinical' to help them further achieve their goals." Andrew Donarumo, Chief Technology Officer at MedSec Englert will continue to assist MedSec in creating security options for hospitals as an advisor. Englert brings to the position extensive understanding of clinical settings and medical technologies. His experience covers more than 30 years of technical and operational leadership in the healthcare and life sciences sector with an emphasis on creating strategic direction, enhancing operations, and undertaking business optimization and transformation efforts that are enabled by data and technology. In addition to governance and operations, vulnerability and patch management, incident response, medical device alerts, and SOC integration, Phil has led the development of medical device security programmes that have made it possible to prioritise strategic initiatives that will have an impact and carry out efficient maintenance and response tasks. In the past, he oversaw the development of strategy and tactics for a $250 million MedTech services business that supported over 130 Acute Care hospitals in 22 states.

Read More

HEALTH TECHNOLOGY

FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US

LifeTech Scientific Corporation | September 06, 2022

LifeTech Scientific Corporation is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States, meaning that all patient enrollment of the clinical trial will be fully covered by the USA medical insurance. This is expected to facilitate the marketing and registration process of the innovative device in the United States and provide strong clinical data to support the development of the device in the global market. The investigator-initiated pre-market clinical trial received FDA approval in March 2022. This prospective, randomized, controlled, multicenter clinical trial aims to evaluate the safety and efficacy of the implantation of LAmbre™ Plus LAA occluder in non-valvular atrial fibrillation patients with large and/or irregularly shaped appendages, as compared to oral anticoagulants. The trial is planning to enroll more than 3,000 subjects from up to 75 investigational sites in the United States and undertake more than 1,500 implantations of the LAmbre™ Plus LAA occluders at a fee. After reaching the established clinical objectives and conditions, the company will submit the marketing application of the device to the FDA. "This is a great milestone in LifeTech's international roadmap. Our LAA occluders had been successfully implanted in the United States on a basis of 'compassionate use', providing a new treatment for non-valvular atrial fibrillation patients with irregularly shaped appendages. Today, the approval for the first ever USA based investigator-initiated pre-market clinical trial and the medical insurance coverage gives us a greater confidence to further accelerate our process for providing this innovative, safe and effective stroke prevention solution to patients in the United States," Mr. Xie Yuehui, Chairman and CEO, LifeTech Scientific Corporation About the LAmbre™ Plus LAA Closure System LAmbre™ Plus LAA Closure System is independently developed by LifeTech Scientific Corporation. The device closes patient's left atrial appendage through percutaneous occlusion procedure to prevent stroke caused by detachment of thrombus from the left atrial appendage. LAmbre™ Plus LAA Closure System is a structural optimized version of the LAmbre™ LAA Closure System, which is an advanced medical device in the industry in terms of design and technology, and currently it has been widely used in over 40 countries with nearly 20,000 cases in clinical application around the world. About LifeTech Scientific Corporation Established in 1999, LifeTech Scientific Corporation (1302.HK) is committed to the R&D, manufacture, and sales of minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases. The company has a comprehensive product portfolio in the treatment of structural heart diseases, peripheral vascular diseases, bradycardia, neurological, neoplastic and respiratory diseases, alongside a unique iron-based bioresorbable technology. To date, 14 of the company's products have been approved as innovative medical devices by the National Medical Products Administration, and with a global reach of over 100 countries and regions, the company is currently one of the few domestic companies in China with a highly internationalized business structure.

Read More

FUTURE OF HEALTHCARE

Anumana Collaborates with Leading Global Health Care Company to Detect Heart Disease Using Artificial Intelligence

Anumana, Inc. | July 14, 2022

Anumana, Inc., an AI-driven health technology company and portfolio company of nference, has launched a multi-year strategic collaboration with Novartis Pharmaceuticals Corporation (“Novartis”) to deploy a series of artificial intelligence powered software solutions that will detect hidden cardiovascular conditions. The collaboration will drive development and delivery of electrocardiogram (ECG) AI algorithms to help physicians accelerate detection and intervention for patients with previously undetected life-threatening heart disease. The ECG AI algorithm is still in development and not yet FDA authorized for commercial clinical use. The collaboration will support Anumana’s efforts to implement AI-enabled diagnostic software that can detect signals from ECGs that humans cannot interpret. The collaboration will initially focus on cardiovascular diseases. Working with its expert partners from Mayo Clinic, Anumana will deploy novel solutions that use AI to analyze an ECG, a widely available, painless test that records the heart’s electrical signals to identify undiagnosed left ventricular dysfunction, or a weak heart pump, which can lead to heart failure. The AI will also screen for atherosclerotic cardiovascular disease, which can lead to heart attack and stroke. In addition, an evidence-based, digital point-of-care solution will be developed to guide in optimizing guideline-directed medical therapies with the aim to lower risk for potentially avoidable hospitalizations and cardiovascular death. “Anumana technology is designed to help physicians identify patients who are at maximum risk of heart failure, long before they develop symptoms. Bringing together premier global organizations will allow us to expand access to best-in-class, AI-powered digital tools to benefit patients through earlier detection and intervention, when and where health care providers need it most.” Murali Aravamudan, CEO of Anumana “Many heart diseases develop for years before signs and symptoms appear, but the first event may be life threatening,” said Paul Friedman, M.D., Chair of the Department of Cardiovascular Medicine at Mayo Clinic and Chair of Anumana’s Mayo Clinic Board of Advisors. “AI enables us to uncover hidden signals our bodies transmit to detect otherwise occult heart diseases, potentially years before symptoms appear. This collaboration has the potential to transform the use of a ubiquitous inexpensive test, the ECG, with the aim of democratizing disease detection and helping medical care teams to proactively manage heart disease ahead of time and prevent some clinical events from ever happening.” “Cardiovascular disease is a widespread and multifactorial disease and, in order to mitigate its impact, we must look beyond therapeutic innovation and reimagine how we approach cardiovascular care,” said Victor Bulto, President, Novartis Innovative Medicines US. "Novartis is proud to collaborate with Anumana on innovative and data-driven solutions to better predict the risk of life-threatening heart disease, further driving forward our commitment to improving patient experiences and population health outcomes in this patient population.” The Mayo Clinic Cardiology team, led by Dr. Friedman, pioneered the application of AI in cardiology and developed several algorithms based on millions of ECGs, including a low ejection fraction algorithm that received FDA Breakthrough Device Designation in 2019 and Emergency Use Authorization for COVID-19 in 2020. Further validating the technology, a recent study presented by Mayo Clinic used a modified version of Anumana’s 12-lead ECG algorithm to detect left ventricular dysfunction with single-lead ECGs in smartwatches. These algorithms are licensed to Anumana for development of clinical solutions and have been validated by over 30 peer-reviewed publications, including a first of its kind prospective clinical impact study on low ventricular ejection fraction that was published in Nature Medicine in 2021. These software solutions are currently in development with each algorithm as a candidate for marketing authorization through an FDA De Novo request. About Anumana Anumana, an AI-driven health technology company and a portfolio company of nference and Mayo Clinic Platform, is harnessing industry-leading AI and translational science to decode the electrocardiogram as never before – as a deep predictive tool and biomarker of disease – empowering care providers to help patients early. Anumana algorithms have been developed, trained, and validated using clinical data from Mayo Clinic and are undergoing rigorous clinical trial validation. Anumana is developing AI-enabled ECG algorithms for real-world physician use, integrating point-of-care applications into existing workflows, thereby reducing costs and enhancing quality of life. Anumana’s AI-enabled tools can diagnose hidden conditions earlier than ever before. Anumana’s algorithms are investigational medical devices and have not yet received regulatory approval or clearance.

Read More